Abstract:Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly valuable treatment option for cancer and has recently emerged with hundreds of clinical trials paving the way to finally achieve market authorization. Advantages of NK cell therapies include the use of allogenic cell sources, off-the-shelf availability, and no risk of graft-versus-host disease (GvHD). Allogeneic NK cell therapies have reached the clinical stage as ex vivo expanded and differentiated non-engineered cells, as chimeric antigen receptor (CAR)-engineered or CD16-engineered products, or as combination therapies with antibodies, priming agents, and other drugs. This review summarizes the recent clinical status of allogeneic NK cell-based therapies for the treatment of hematological and solid tumors, discussing the main characteristics of the different cell sources used for NK product development, their use in cell manufacturing processes, the engineering methods and strategies adopted for genetically modified products, and the chosen approaches for combination therapies. A comparative analysis between NK-based non-engineered, engineered, and combination therapies is presented, examining the choices made by product developers regarding the NK cell source and the targeted tumor indications, for both solid and hematological cancers. Clinical trial outcomes are discussed and, when available, assessed in comparison with preclinical data. Regulatory challenges for product approval are reviewed, highlighting the lack of specificity of requirements and standardization between products. Additionally, the competitive landscape and business field is presented. This review offers a comprehensive overview of the effort driven by biotech and pharmaceutical companies and by academic centers to bring NK cell therapies to pivotal clinical trial stages and to market authorization.

NK cell-based cancer immunotherapy: from basic biology to clinical development

NK cell-based cancer immunotherapy: from basic biology to clinical application.

Natural killer cell-based cancer immunotherapy: from basics to clinical trials

Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

NK Cell Therapy: A Rising Star in Cancer Treatment

NK Cell-Based Immunotherapy for Malignant Diseases

Natural killer cells: a promising immunotherapy for cancer

NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities

Development of NK cell-based cancer immunotherapies through receptor engineering

Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

Application of Natural Killer Cells in Cancer Treatment and Its Clinical Progress

Current status and future perspective of natural killer cell therapy for cancer.

Natural Killer Cell Lines in Tumor Immunotherapy

The basic biology of NK cells and its application in tumor immunotherapy

Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

Natural killer cells in cancer biology and therapy

NK cell-based tumor immunotherapy

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Natural killer cells in cancer immunotherapy

Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities